logo-loader
viewTissue Regenix Group PLC

Tissue Regenix focused on securing further strategic partnerships

"We are now in the position of really trying to kick on in 2018'', Couldwell says

Steve Couldwell, chief executive of Tissue Regenix PLC (LON:TRX), tells Proactive that 2017 has been a year of transformation, boosted by the acquisition of CellRight.

“That was the transformation the company really needed, and the integration of that business has gone extremely well ... we are now in the position of really trying to kick on in 2018'', Couldwell says.

Since the end of the reporting period, the group's announced strategic partnerships with ARMS Medical for DermaPure and with Arthrex for the distribution of CellRight’s ‘BioRinse’ portfolio.

Quick facts: Tissue Regenix Group PLC

Price: 1.05 GBX

AIM:TRX
Market: AIM
Market Cap: £12.31 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix increasing throughput in its facility to meet 'exceptional...

Tissue Regenix PLC's (LON:TRX) Gareth Jones caught up with Proactive's Andrew Scott to update on developments in the regenerative medical devices maker's second half. ''The focus is really on increasing throughput in our San Antonia facility in the United States to allow us to meet the demand...

on 19/12/19

2 min read